HALKUFF DAWN sold 17.4% of their position (20K shares) of XERIS BIOPHARMA HOLDINGS, INC. on the open market
Open‑market sale worth $121.9K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/5/2026ACC: 0001743658-26-000002
Director
Since Oct 2021
+37.19K
Net shares
Net buyer
$121.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
57.19K acquired · 20K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−20K
Price / share
$6.09
Trade value
$121.89K
% of position
17.4%
6/4/2026
115K→95K
Common Stock
Direct
Shares
+24.19K
Price / share
—
Trade value
—
% of position
25.5%
6/4/2026
95K→119.19K
Total
Net shares
+4.19K
Net value
-$121.89K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/4/2026 | S · Sale | −20K | $6.09 | $121.89K | 17.4% | 115K | 95K |
| Common Stock Direct | 6/4/2026 | A · Award | +24.19K | — | — | 25.5% | 95K | 119.19K |
| Total | +4.19K | -$121.89K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
33K shares
Shares
+33K
Strike price
6.15
Held after
33K
Exercisable
—
6/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock33K shares | 6/4/2026 | A · Award | +33K | 6.15 | — | 33K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned5.41K
Total
5.41K indirect5.41K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 5.41K | Indirect |
| Total | 5.41K | 5.41K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported